- $566.63m
- $20.41m
- $0.13m
- 42
- 16
- 60
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.87 | ||
| Price to Tang. Book | 0.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4,358.73 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.33% | ||
| Return on Equity | -31.53% | ||
| Operating Margin | -199946.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.66 | 7.76 | 10.65 | 84.68 | 0.13 | n/a | n/a | -33.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.
Directors
- Richard Klausner CHM (69)
- Elizabeth Homans CEO (51)
- Charles Newton CFO (51)
- Stephen Hill COO (50)
- Lisa Ryan CHO (54)
- Nicholas Restifo EVP (60)
- Richard Goold CIO (61)
- Gary Lee CSO
- Heather Turner GCN (48)
- Tina Albertson OTH (48)
- Hans Bishop IND (57)
- Otis Brawley IND (62)
- Elizabeth Nabel IND (69)
- Robert Nelsen IND (58)
- William Rieflin IND (61)
- Lynn Seely IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 29th, 2018
- Public Since
- June 17th, 2021
- No. of Shareholders
- 60
- No. of Employees
- 224
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 254,096,311
- Address
- 201 Haskins Way, Suite 301, SOUTH SAN FRANCISCO, 94080
- Web
- https://lyell.com/
- Phone
- +1 6506950677
- Auditors
- Ernst & Young LLP
Similar to LYEL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:13 UTC, shares in Lyell Immunopharma are trading at $2.23. This share price information is delayed by 15 minutes.
Shares in Lyell Immunopharma last closed at $2.23 and the price had moved by -0.45% over the past 365 days. In terms of relative price strength the Lyell Immunopharma share price has underperformed the S&P500 Index by -17.16% over the past year.
The overall consensus recommendation for Lyell Immunopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Lyell Immunopharma does not currently pay a dividend.
Lyell Immunopharma does not currently pay a dividend.
Lyell Immunopharma does not currently pay a dividend.
To buy shares in Lyell Immunopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.23, shares in Lyell Immunopharma had a market capitalisation of $566.63m.
Here are the trading details for Lyell Immunopharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LYEL
Based on an overall assessment of its quality, value and momentum Lyell Immunopharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lyell Immunopharma is $6.00. That is 169.06% above the last closing price of $2.23.
Analysts covering Lyell Immunopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.85 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lyell Immunopharma. Over the past six months, its share price has outperformed the S&P500 Index by +22.14%.
As of the last closing price of $2.23, shares in Lyell Immunopharma were trading +5.57% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lyell Immunopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lyell Immunopharma's management team is headed by:
- Richard Klausner - CHM
- Elizabeth Homans - CEO
- Charles Newton - CFO
- Stephen Hill - COO
- Lisa Ryan - CHO
- Nicholas Restifo - EVP
- Richard Goold - CIO
- Gary Lee - CSO
- Heather Turner - GCN
- Tina Albertson - OTH
- Hans Bishop - IND
- Otis Brawley - IND
- Elizabeth Nabel - IND
- Robert Nelsen - IND
- William Rieflin - IND
- Lynn Seely - IND